Zanamivir: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), NYE METODER (Norway) and SMC (Scotland) recommended or restricted zanamivir, while CIPM (Spain) and HAS (France) did not recommend it.
Assessment has run over 8.1 years, from 9 May 2013 at PHARMAC (New Zealand) to 10 Jun 2021 at CIPM (Spain).
PHARMAC (New Zealand) changed its position: recommended on 9 May 2013, not recommended by 9 May 2013.
No assessment is on file from PBAC (Australia), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
Against its own class, zanamivir is an outlier: 57% of its decisive outcomes were positive, where molecules sharing ATC class J05A average 87%.
PHARMAC (New Zealand) was first to assess zanamivir, on 9 May 2013; CIPM (Spain) did not open a file until 10 Jun 2021 — an unusually long tail of 8.1 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 4 years in total.
PHARMAC (New Zealand) is the only agency to have returned to zanamivir, recording 2 separate entries.
6 of the 18 agencies in this archive hold a record for zanamivir.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 10 Jun 2021 | Indicaciones terapéuticas: Dectova está indicado para el tratamiento de la infección por el virus de la gripe A o B comp… | not financed by the SNS · art. 92 e | source |
| NYE METODER (Norway) | 13 Dec 2020 | Legemiddel til behandling av pasienter i sykehus med alvorlig influensa A eller B- infeksjon | introduced | source |
| HAS (France) | 1 Apr 2020 | Listing (Transparency Committee) | SMR insufficient | source |
| SMC (Scotland) | 9 Dec 2019 | Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when: • The patient’s influe… | accepted | source |
| AWMSG (Wales) | 24 Oct 2019 | Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patie… | recommended (limited) | source |
2 further decisions for zanamivir, across 1 agency, are not shown here. They link to 2 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 7 decisions for zanamivir from 6 agencies, 2013 to 2021. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.